Effect of calcitonin on vertebral and other fractures

QJM: An International Journal of Medicine

Volumn 92, Issue 3, 1999, Pages 143-149

  Kanis, J A ^a   Mccloskey, E V ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; VITAMIN D;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; FRACTURE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

EID: 0033016224     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.3.143     Document Type: Article

References (24)

1. Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials. Osteoporosis Int 1998; 7:165-74.
2. Plosker GL, McTavish D. Intranasal calcitonin (salmon calcitonin): A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996; 8:378-400.
3. Wallach S, Farley JR, Baylink DJ, et al. Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 1993; 52:335-9.
4. Burckhardt P, Burnand B. The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis. Osteoporosis Int 1993; 3:24-30.
5. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. A dose-response study. Br Med J 1992; 305:556-61.
6. Stock JL, Avioli LV, Baylink DJ, Chesnut C, Genant HK, Maricic MJ, Silverman SL, Schaffer AV, Beinblatt J, for the PROOF study group. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three year interim results of the PROOF study. J Bone Miner Res 1997; 12 (suppl 1 ):S149.
7. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992; 16:131-8.
8. Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin. A prospective study. Calcif Tissue Int 1995; 56:181-5.
9. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 4:629-32.
10. Agrawal R, Wallach S, Cohn S, Tessier M, Verch R, Hussain M, Zanzi I. Calcitonin treatment of osteoporosis. In: Calcitonin 1980. Proceedings of an international symposium held in Milan, October 1980. Amsterdam, Excerpta Medica, 1980:237-46.
11. Ellerington MC, Hillard TC, Whitcroft SIJ, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59:6-11.
12. Gennari CL, Chierichetti SM, Bigazzi S, Fusi L, Gonelli S, Ferrara R, Zacchei F. Comparative effects on bone mineral content of calcium and calcium plus calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38:455-64.
13. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, Miltnick H, Ales K, Schwartzberg P. A randomised controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temperal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58:73-80.
14. Perez MA, Garcia FJB, Clabozo M, et al. Estudio comparativo multicentries de la calcitonina sintetica de salmon administrada por via nasal en el tratamiento de la osteoporosis post-menopausica establecida. Ann Med Intern 1995; 12:12-16.
15. Ringe J-D, Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33:35-9.
16. Ringe JD. Behandlung der primaren Osteoporosis mit Calcium und Lachscalcitonin. Dtsch Med Wschr 1990; 115:1176-82.
17. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Stat M, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis, A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328:1747-52.
18. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33:295-303.
19. Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long-term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49:1099-102.
20. Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamon A, Meunier PJ. Treatment of high remodelling vertebral osteoporosis with human calcitonin: a two year double-blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen, Osteopress, 1990:1430-3.
21. Mazzuoli C, Gennari C, Passeri M, Acca M, Camporeale M, Pioli G. Hip fractures in Italy: epidemiology and preventive efficacy of bone active drugs. Bone 1994; 14 (suppl. 1):S81-4.
22. Kanis JA, Johnell O, Gullberg B, Allander E, Dilzen G, Gennari C, Lopes Vaz AA, Lyritis G, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C. Evidence for the efficacy of drugs affecting bone metabolism in the prevention of hip fracture. Br Med J 1992; 305:1124-8.
23. Royal College of Physicians. Clinical guidelines for strategies to prevent and treat osteoporosis. London, Royal College of Physicians, 1998.
24. World Health Organisation. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva, WHO, 1998.